



Gacci M1, Sebastianelli A1, Russo G I2, Cimino S2, Salvi M1, Spatafora P1, Carini M3, Senni S1, Moncada I4, Gravas S5, Giuliano F6, Morgia G2  
 1. Department of Urology, Careggi Hospital, University of Florence (Italy), 2. Department of Urology, Policlinico Hospital, University of Catania, Catania, Italy, 3. Department of Urology, Careggi Hospital, University of Florence (Italy) y of Florence (Italy), 4. Department of Urology, Hospital La Zarzuela, Madrid, Spain, 5. Department of Urology, University Hospital of Larissa, Larissa, Greece, 6. AP-HP, Neuro-Uro-Andrology, Versailles Saint Quentin en Yvelines University, Versailles, France

### Hypothesis / Aim of the Study

Overactive bladder (OAB)/storage LUTS, a multifactorial and common condition, affecting 30–40% of the population >75 yr of age, is characterized by nocturnal micturition and urgency episodes, with a consequent worsening of quality of life. The hypothesis that we wanted to verify with this systematic review and meta-analysis is the assessment of mirabegron efficacy, a  $\beta_3$ -adrenoceptor agonist, in two different dosages in the reduction of urgency and nocturia episodes.


### Study design, Materials and Methods

A MEDLINE, EMBASE, Cochrane Library, and Science Citation Index Expanded Medline search was performed to identify all published randomized-placebo controlled clinical trials (RCTs) evaluating mirabegron for the treatment of OAB/storage LUTS, in reducing the number of nocturia and urgency episodes.


### Results

The search extracted 491 studies from the relevant databases. After a thorough evaluation of each study, 8 RCTs were identified. Mirabegron 50 mg (Mir50), mirabegron 100 mg (Mir100) and tolterodine 4 mg (Tol) were all significantly associated with the reduction of urgency episodes when compared to placebo. Mir50 showed greater efficacy versus placebo in the reduction of nocturia episodes (weighted mean difference [WMD]: -0.13; p=0.003) and versus Tol (WMD= -0.07; p=0.03). Conversely, Tol was not associated with a significant reduction of nocturia episodes compared to placebo (WMD: -0.05; p=0.36). Furthermore, Mir100 was not statistically superior to Mir50 for nocturnal episodes (WMD: -0.07; p=0.17). When assessing the reduction of urgency episodes, Mir50 was statistically better than placebo (WMD: -0.53; p<0.00001) but not than Tol (WMD: -0.02; p=0.85), which was associated with greater efficacy than placebo (WMD: -0.29; p=0.01). Mir100 was statistically similar to Mir50 (WMD: 0.0; p=1.00) and Tol (WMD: -0.29; p=0.52).

**Figure 1. Weighted mean difference for nocturia.**



**Figure 2. Weighted mean difference for urgency.**



### Interpretation of Results

The efficacy of Mirabegron presents a statistically stronger evidence than Tol in reducing nocturia episodes. Every investigated dosage bring to the same conclusion. An explanation of this effect can be found in the different target of the drugs and the consequently different effect. Muscarinic receptors are not related to nocturia at the investigated dosage, but higher dosage can bring more adverse effects. At present time  $\beta_3$ -adrenoceptor agonist have the advance to reduce nocturia episodes compared to other drugs. Results showed that on urgency Mir50 and Tol have the same outcomes, so both  $\beta_3$ -adrenoceptor receptors and muscarinic receptors can act on urgency. The same effectiveness of both Mir50 and Mir100 on meta-analysis can be explained from the drug's pharmacokinetic or the consequent regulation of the receptor or the reaching of the maximum drug efficacy.

### Concluding Message

No statistical differences were found among Mir50 and Tol in reducing urgency episodes while Mir50 demonstrated a significant evidence in reducing nocturia. Mir100 did not show a greater efficacy in reducing the investigated LUTS (urgency and nocturia) if compared with Mir50.